Chronic kidney disease and the risk of incident gout among middle-aged men: A seven-year prospective observational study

Arthritis and Rheumatism

Volumn 65, Issue 12, 2013, Pages 3271-3278

  Krishnan, Eswar ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; CHLORTALIDONE; COLCHICINE; CREATININE; GUANETHIDINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE PLUS SPIRONOLACTONE; METHYLDOPA; PROBENECID; PROPRANOLOL; RESERPINE; TRIAMTERENE; URATE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FOLLOW UP; GOUT; HEMATURIA; HUMAN; HYPERTENSION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR;

ADULT; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GOUT; HUMANS; HYPERURICEMIA; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RENAL INSUFFICIENCY, CHRONIC; RISK;

EID: 84889034841     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38171     Document Type: Article

References (48)

1. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-52.
2. Yu Ta-F, Berger LR,. The kidney in gout and hyperuricemia. Mount Kisco (NY): Futura Publishing Co; 1982.
3. Terkeltaub R, Bushinsky DA, Becker MA,. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther 2006; 8 Suppl 1: S4.
4. Coombs FS, Pecora LJ, Thorogood E, Consolazio WV, Talbott JH,. Renal function in patients with gout. J Clin Invest 1940; 19: 525-35.
5. Rieselbach RE, Sorensen LB, Shelp WD, Steele TH,. Diminished renal urate secretion per nephron as a basis for primary gout. Ann Intern Med 1970; 73: 359-66.
6. Sorensen LF,. Gout secondary to chronic renal disease: studies on urate metabolism. Ann Rheum Dis 1980; 39: 424-30.
7. Steele TH, Rieselbach RE,. The contribution of residual nephrons within the chronically diseased kidney to urate homeostasis in man. Am J Med 1967; 43: 876-86.
8. Avram Z, Krishnan E,. Hyperuricaemia-where nephrology meets rheumatology [review]. Rheumatology (Oxford). 2008; 47: 960-4.
9. Centers for Disease Control and Prevention. Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007; 56: 161-5.
10. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-47.
11. Krishnan E,. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS One 2012; 7: e50046.
12. Richet G, Mignon F, Ardaillou R,. Secondary gout in chronic nephropathies. Presse Med 1965; 73: 633-8.
13. Sarre H,. Goutte secondaire a l'insuffisiance renale Travaus de Congres International de la Goutte et de la Lithiase Urique. Paris: Evian; 1964. p. 244-55.
14. Yu TF, Berger L,. Renal disease in primary gout: a study of 253 gout patients with proteinuria. Semin Arthritis Rheum 1975; 4: 293-305.
15. Cea Soriano L, Rothenbacher D, Choi HK, Garcia Rodriguez LA,. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther 2011; 13: R39.
16. Choi HK, Atkinson K, Karlson EW, Curhan G,. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005; 165: 742-8.
17. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG,. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64: 267-72.
18. Liu Q, Gamble G, Pickering K, Morton S, Dalbeth N,. Prevalence and clinical factors associated with gout in patients with diabetes and prediabetes. Rheumatology (Oxford) 2012; 51: 757-9.
19. Fuldeore MJ, Riedel AA, Zarotsky V, Pandya BJ, Dabbous O, Krishnan E,. Chronic kidney disease in gout in a managed care setting. BMC Nephrol 2011; 12: 36.
20. Liote F, Lancrenon S, Lanz S, Guggenbuhl P, Lambert C, Saraux A, et al. GOSPEL: Prospective survey of gout in France. Part I. Design and patient characteristics (n=1003). Joint Bone Spine 2012; 79: 464-70.
21. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS,. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003 Jan; 41: 1-12.
22. Sherwin R, Kaelber CT, Kezdi P, Kjelsberg MO, Thomas HE Jr,. The multiple risk factor intervention trial (MRFIT). II. The development of the protocol. Prev Med 1981; 10: 402-25.
23. Zukel WJ, Paul O, Schnaper HW,. The multiple risk factor intervention trial (MRFIT). I. Historical perspective. Prev Med 1981; 10: 387-401.
24. Neaton JD, Grimm RH Jr, Cutler JA,. Recruitment of participants for the multiple risk factor intervention trial (MRFIT). Control Clin Trials 1987; 8 Suppl: 41S-53S.
25. Gelber AC, Klag MJ, Mead LA, Thomas J, Thomas DJ, Pearson TA, et al. Gout and risk for subsequent coronary heart disease: The Meharry-Hopkins Study. Arch Intern Med 1997; 157: 1436-40.
26. McAdams MA, Maynard JW, Baer AN, Kottgen A, Clipp S, Coresh J, et al. Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol 2011; 38: 135-41.
27. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G,. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093-103.
28. Widdowson GM, Kuehneman M, DuChene AG, Hulley SB, Cooper GR,. Quality control of biochemical data in the Multiple Risk Factor Intervention Trial: central laboratory. Control Clin Trials 1986; 7 Suppl: 17S-33S.
29. Sherwin R, Kaelber CT, Kezdi P, Kjelsberg MO, Thomas HE Jr,. The multiple risk factor intervention trial (MRFIT). II. The development of the protocol. Prev Med 1981; 10: 402-25.
30. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
31. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 Suppl 1: S1-266.
32. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH,. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008; 168: 1104-10.
33. Krishnan E, Kwoh C, Schumacher HR, Kuller L,. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49: 298-303.
34. Krishnan E, Baker JF, Furst DE, Schumacher HR,. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006; 54: 2688-96.
35. Krishnan E,. Gout and coronary artery disease: epidemiologic clues. Curr Rheumatol Rep 2008; 10: 249-55.
36. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
37. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35 Suppl 1: S64-71.
38. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C,. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004; 24: e13-8.
39. Cleves MA, Gould WW, Gutierrez RG,. An introduction to survival analysis using stata. College Station (TX): Stata Press; 2002.
40. Breslow NE, Day NE,. Statistical methods in cancer research. Lyon: IARC Scientific Publications; 1980.
41. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE,. Epidemiology of gout: is the incidence rising? J Rheumatol 2002; 29: 2403-6.
42. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF,. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900.
43. Juul S,. An introduction to stata for health researchers. College Station (TX): Stata Press; 2006.
44. Lipkowitz MS,. Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep 2012; 14: 179-88.
45. Gibson T,. Hyperuricemia, gout and the kidney. Curr Opin Rheumatol 2012; 24: 127-31.
46. Rodriguez G, Soriano LC, Choi HK,. Impact of diabetes against the future risk of developing gout. Ann Rheum Dis 2010; 69: 2090-4.
47. Ahmad A, Roderick P, Ward M, Steenkamp R, Burden R, O'Donoghue D, et al. Current chronic kidney disease practice patterns in the UK: a national survey. QJM 2006; 99: 245-51.
48. Curiel RV, Guzman NJ,. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. Semin Arthritis Rheum 2012; 42: 166-78.